Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations. by Ferraioli, Giovanna et al.
Ultrasound in Med. & Biol., Vol. 44, No. 12, pp. 24192440, 2018
Copyright © 2018 The Author(s). Published by Elsevier Inc. on behalf of World Federation for Ultrasound in Medicine & Biology.
This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Printed in the USA. All rights reserved.
0301-5629/$ - see front matter
https://doi.org/10.1016/j.ultrasmedbio.2018.07.008 ReviewLIVER ULTRASOUND ELASTOGRAPHY: AN UPDATE TO THEWORLD
FEDERATION FOR ULTRASOUND IN MEDICINE AND BIOLOGY GUIDELINES AND
RECOMMENDATIONS
TAGGEDPD1X X IOVANNA FERRAIOLI, D2X X* D3X XVINCENT WAI-SUN WONG, D4X Xy D5X XLAURENT CASTERA, D6X Xz D7X XANNALISA BERZIGOTTI, D8X Xx
D9X XIOAN SPOREA, D10X X{ D11X XCHRISTOPH F DIETRICH,D12X X║ D13X XBYUNG IHN CHOI, D14X X# D15X XSTEPHANIE R. WILSON, D16X X**
D17X XMASATOSHI KUDO, D18X Xyy and D19X XRICHARD G. BARRD20 X Xzz TAGGEDEND
*Ultrasound Unit, Department of Clinical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, School of
Medicine, University of Pavia, Pavia, Italy; yDepartment of Medicine and Therapeutics, Chinese University of Hong Kong, Hong
Kong; zService d’Hepatologie, Hopital Beaujon, Clichy, Assistance Publique-Hopitaux de Paris, INSERM UMR 1149 CRI,
Universite Denis Diderot Paris-VII, Paris, France; x Swiss Liver Center, Hepatology, University Clinic for Visceral Surgery and
Medicine, Inselspital, University of Bern, Switzerland; {Department of Gastroenterology and Hepatology, University of Medicine
and Pharmacy, Timisoara, Romania; ║Medizinische Klinik 2, Caritas-Krankenhaus, Bad Mergentheim, Germany; # Department of
Radiology, Seoul National University Hospital, Seoul, South Korea; **Department of Diagnostic Imaging, Foothills Medical Centre,
University of Calgary, Calgary, Alberta, Canada; yyDepartment of Gastroenterology and Hepatology, Kindai University School of
Medicine, Osaka Sayama, Japan; and zzDepartment of Radiology, Northeastern Ohio Medical University and Southwoods Imaging,
Youngstown, Ohio, USA
(Received 1May 2018; revised 2 July 2018; in final from 13 July 2018)A
Radiol
ing, 76
rgbarr@Abstract—The World Federation for Ultrasound in Medicine and Biology has produced these guidelines for the
use of elastography techniques in liver diseases. For each available technique, the reproducibility, results and lim-
itations are analyzed, and recommendations are given. This set of guidelines updates the first version, published
in 2015. Since the prior guidelines, there have been several advances in technology. The recommendations are
based on the international published literature, and the strength of each recommendation is judged according to
the Oxford Centre for Evidence-Based Medicine. The document has a clinical perspective and is aimed at assess-
ing the usefulness of elastography in the management of liver diseases. (E-mail: rgbarr@zoominternet.
net) © 2018 The Author(s). Published by Elsevier Inc. on behalf of World Federation for Ultrasound in
Medicine & Biology. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Key Words: World Federation for Ultrasound in Medicine and Biology guidelines, Liver diseases, Elastography,
Transient elastography, Acoustic radiation force impulse, Shear wave elastography, Strain elastography, Liver,
Ultrasound, Liver fibrosis, Liver stiffness, Focal liver lesions, Portal hypertension.INTRODUCTION
Elastography has been used to evaluate liver stiffness for
more than 10 y. As chronic liver damage results in
hepatic fibrosis, characterized by an increase of extracel-
lular matrix produced by fibroblast-like cells, the liver
becomes stiffer than normal. Elastography can be used
to assess liver stiffness non-invasively. It measures tis-
sue behavior when an external mechanical actuation orddress correspondence to: Richard G. Barr, Department of
ogy, Northeastern Ohio Medical University Southwoods Imag-
23 Market Street, Youngstown, OH 44512, USA. E-mail:
zoominternet.net
2419an internal acoustic radiation force is applied and can be
monitored by ultrasound (US) or magnetic resonance
imaging (MRI).
This document reviews the several US-based elas-
tography techniques available clinically. Magnetic reso-
nance elastography is not discussed but is described
elsewhere (Barr et al. 2016b). The several US-based
elastography techniques have been extensively described
in Part 1 (Shiina et al. 2015). These techniques differ in
the physical approaches used and can be grouped into
three major types: (i) transient elastography (TE), which
uses a mechanical external push; (ii) acoustic radiation
force impulse (ARFI) techniques, which use an acoustic
2420 Ultrasound in Medicine & Biology Volume 44, Number 12, 2018internal push; and (iii) strain elastography (SE) tech-
nique, which uses frame-to-frame differences (tissue
deformation) with stress, caused by pressing the body
surface or by internally occurring physiologic motion.
The ARFI techniques can be divided into point shear
wave elastography (p-SWE) and 2-D shear wave elas-
tography (2-D SWE) techniques. The shear wave-based
techniques (TE and ARFI techniques) measure the
speed of shear waves in tissues. The shear waves are
generated by an external mechanical push in TE or by
the push pulse of a focused ultrasound beam in the
ARFI techniques. For both of these techniques, the
shear wave speed calculated, which is related to liver
stiffness, can be converted into kilopascals, the unit of
Young’s modulus E (3rv2, where r is the tissue density
and v is the speed of the shear wave), assuming that the
tissue is purely elastic, incompressible, its elastic
response is linear and that the tissue density is always
1000 kg/m3. It is important to note that magnetic reso-
nance elastography (MRE) reports the shear modulus in
kilopascals and is three times smaller than the Young’s
modulus used to report the results of the ultrasound
techniques (Barr et al. 2016b).
Guidelines on the use of US elastography for the
assessment of liver diseases were produced by the World
Federation for Ultrasound in Medicine and Biology
(WFUMB) a few years ago (Ferraioli et al. 2015); how-
ever, this is a very rapid growing field and new evidence
and improvements are available since that release.
Our objectives were to determine, based on the evi-
dence from the literature, what is new since the previous
release of the WFUMB guidelines (Ferraioli et al. 2015),
regarding the impact of elastography on reduced use
and/or replacement of liver biopsy for diffuse liver dis-
eases. The potential role of elastography in the character-
ization of focal liver lesions is also discussed.
The authors met in Chicago in December 2017 to
discuss and reach consensus on the use of liver elastogra-
phy for liver stiffness measurements. Recommendations
were made and graded using the Oxford classification,
including Level of Evidence (LoE), Grade of Recom-
mendation (GoR) and proportion of agreement (Oxford
Centre for Evidence-Based Medicine [OCEBM] 2009).Terminology, techniques, systems
Transient elastography. Transient elastography is
a 1-D technique performed with the FibroScan system
(Echosens, Paris, France). The technique has been fully
described (Ferraioli et al. 2015).
The newer version of TE, available on the Fibro-
Scan 502 Touch system, allows measurement of the
decrease in amplitude of ultrasound signal in the liver,
using the controlled attenuation parameter (CAP) tool.The CAP results are given in decibels per meter (dB/m),
range from 100 to 400 and are related to the amount of
fat in the liver. The system has three types of probes
with different ultrasound frequencies. The M probe has
an ultrasound frequency of 3.5 MHz for measurement at
a depth from 2.5 to 6.5 cm from the skin. The XL probe,
with an ultrasound frequency of 2.5 MHz for measure-
ment from 3.5 to 7.5 cm, is used when the skin-to-liver
capsule distance is >2.5 cm. The software of the system
controls the choice between the two probes based on this
distance. The S probe, with an ultrasound frequency of
5.0 MHz for measurements between 1.5 and 5.0 cm, is
usually used in children, when the thoracic diameter is
<75 cm. As of today, CAP is available on the M and XL
probes and is displayed only when the liver stiffness
measurement (LSM) is valid, because it is computed
from the ultrasound signals used for acquiring LSM
(Berzigotti et al. 2018).Acoustic radiation force impulse techniques. Th-
ese techniques are based on the generation of shear
waves by the push pulse of the ultrasound beam. To gen-
erate the tissue displacement, the length of pulse of the
US beam is longer than that used for the B-mode image,
to provide momentum transfer pushes. The techniques
are described in detail elsewhere (Shiina et al. 2015).
The European Federation of Societies for Ultra-
sound in Medicine and Biology (EFSUMB) has recently
updated the guidelines for the use of elastography in the
assessment of liver fibrosis (Dietrich et al. 2017a). We
agree with that terminology.
Acoustic radiation force impulse-based techniques
are available on both the linear and the curvilinear trans-
ducers. For assessment of the liver, generally the curvi-
linear transducer is used (at least in adults). Note that
shear wave speeds are dependent on ARFI pulse fre-
quency; therefore, the values will differ if a linear
higher-frequency probe is used. Manufacturers have pro-
vided quality factors for the measurements (Table 1).
These quality factors evaluate if the stiffness value
reported meets criteria for an accurate measurement.VARIABILITY BETWEEN P-SWE AND 2-D SWE
SYSTEMS
Limitations and system differences
The main limitation of these techniques is that dif-
ferent estimates of shear wave speed (SWS) are obtained
with different systems.
The Quantitative Imaging Biomarker Alliance
(QIBA) committee of the Radiologic Society of North
America (RSNA) performed an inter-laboratory study
of SWS estimation in elastic phantoms. Commercially
available SWE systems were used. A statistically
Table 1. Available equipment








FibroScan The software determines automatically
whether each measurement is successful
or not and controls choice between M+
and XL+ probes based on skin-to-liver
capsule distance (this second option is
available with the newer systems);
10 measurements and IQR/M 30%
Controlled Attenuation Parameter
(CAP) to detect and quantify
liver steatosis.
Point SWE (pSWE) Acuson S2000 and 3000 (Siemens
Healthineers, Germany)
Virtual Touch Quantification (VTQ) If signal/to noise ratio is low, “XXX”
is displayed.
iU22, Epiq series, Affiniti (Philips
Healthcare, Netherlands)
ElastPQ No measurement displayed if signal/to
noise ratio is low; for each measurement
the standard deviation is provided
HI-VISION Ascendus, Arietta 70, Arietta 850
(Hitachi Ltd, Japan)
Shear wave measurement (SWM) No measurement displayed if signal/to
noise ratio is low; net amount of effective
shear wave velocity (VsN) 50%
Combinational elastography
(available on the Arietta 850)
that combines strain and shear
wave elastography.
ATT  attenuation software for
quantification of liver steatosis.
MyLab 9 (Esaote, Italy) QElaXto No measurement displayed if signal/to noise
ratio is low; rate of effective measure for
each value shown in the screen (H,M,L)
HS70 A, RS80 A (Samsung Medison,
South Korea)
S-shearwave Reliable measurement index (RMI)
2-D SWE Aixplorer (SuperSonic Imagine, France) SSI No color displayed if signal/to noise ratio
is low; stability index (SI)
Epiq series (Philips Healthcare, Netherlands) ElastQ No color displayed if signal/to noise ratio
is low; confidence map
Acuson S3000 (Siemens Healthineers, Germany) Virtual Touch IQ
Logiq E9 (GE Healthcare, USA) Pixels remain blank if result is not
“satisfactory”
Aplio 500, i-series (Canon Medical Systems, Japan) Propagation map Shear wave dispersion imaging,
related to tissue viscosity.
Attenuation Imaging (ATI) to
detect and quantify liver steatosis.
Resona series, DC-80 system (Mindray, China) Sound Touch Elastography (STE),
Sound Touch Quantification (STQ)
Reliability map (RLB); stability from
motion in a period of time frames (M-STB)



























Table 2. Recommendations for performing liver elastography
Adherence to a strict protocol is required.
Patient should fast for 4 h before examination.
Exam should be performed with the patient in the supine or slight left
lateral position with the arm raised above the head to increase the
intercostal space.
Measurements should be taken through an intercostal approach at the
location of the best acoustical window.
Measurements should be taken 1.5 to 2.0 cm below the liver capsule to
avoid reverberation artifact. The optimal location for maximum shear
wave generation is 4.04.5 cm from the transducer.
The transducer should be perpendicular to the liver capsule.
Placement of the region of interests should avoid large blood vessels,
bile ducts and masses.
For transient elastography, the appropriate transducer should be
selected based on patient’s body habitus.
Ten measurements should be obtained from 10 independent images, in
the same location, with the median value used for transient elastogra-
phy and point shear wave elastography techniques. Three or five
measurements may be appropriate for 2-D shear wave elastography
when a quality assessment parameter is used.
The IQR/M (interquartile range/median) should be used as a measure
of quality. For kPa measurements the IQR/M should be <0.3 and for
m/s it should be <0.15 for an accurate data set.
2422 Ultrasound in Medicine & Biology Volume 44, Number 12, 2018significant difference in SWS estimates among systems
and a depth-dependent estimate of SWS for each sys-
tem were obtained. The inter-system variability ranged
from 6% to 12%. No statistically significant differen-
ces were found among raters using the same system.
The study also reported very good agreement between
systems (Hall 2013).
It was found that in viscoelastic phantoms, the
deepest focal depth (7.0 cm) yielded the greatest inter-
system variability for each phantom (maximum of
17.7%) as evaluated by the interquartile range (IQR),
and the median SWS estimates for the greatest outlier
system for each phantom/focal depth combination
ranged from 12.7% to 17.6% (Palmeri 2015).
A study has evaluated the variability of SWS
assessed with a p-SWE technique at various depths using
different frequencies. In both the phantom and liver, the
mean velocities as measured by two probes at the same
depth and at different depths differed. The lowest vari-
ability in the phantom was at 4 and 5 cm from surface
with the convex probe and at 2 cm with a linear probe.
In the liver, the depth with lower variability was 4 cm
from the skin with a convex probe and at 3 and 4 cm
with a linear probe (Chang et al. 2013). In another study
on 89 chronic hepatitis C virus (HCV)-infected patients,
the linear probe gave SWS values higher than those
obtained with the convex probe (Potthoff et al. 2013).
This is expected because the SWS is dependent on the
ARFI frequency: The higher the ARFI frequency, the
higher the SWS.
A recent study has evaluated the inter-system and
inter-observer variability of LSMs in patients with vary-
ing degrees of liver stiffness (Ferraioli et al. 2018). The
assessment of LSMs was performed using six US sys-
tems, four with p-SWE and two with 2-D SWE. The
Fibroscan was used as the reference standard. There was
an agreement >0.80 for all pairs of systems. The mean
difference between the values of the systems with 2-D
SWE technique was 1.54 kPa, whereas the maximum
mean difference between the values of three of four sys-
tems with p-SWE technique was 0.79 kPa. The variabil-
ity between measurements obtained with different
systems was higher in stiffer liver. The range of values
obtained with the two 2-D SWE systems paralleled that
of the Fibroscan in cases of very stiff liver (>15 kPa),
whereas the four systems with a p-SWE technology gave
lower values in the higher range of liver stiffness. The
intra-patient concordance for all systems was 0.89 (95%
confidence interval [CI]: 0.830.94). Inter-observer
agreement was >0.90.
Piscaglia et al. (2017) reported that the correlation
between stiffness measurements taken with several sys-
tems (including the Fibroscan) in different intercostal
spaces was good but not perfect.Recommendation 1: Cutoffs for staging liver
fibrosis are system specific. (LoE 1b, GoR A) (10,0,0)TECHNICAL PROCEDURES
For all SWE techniques, adherence to a strict proto-
col is required (Table 2) (Barr et al. 2016b). Patients
should be fasting for at least 4 h, as ingestion of food
increases blood flow to the liver, increasing its stiffness
(Barr et al. 2016b). Ingestion of food can only increase
the liver stiffness, therefore, if patients eat and their stiff-
ness values are normal, they have no or mild fibrosis.TRANSIENT ELASTOGRAPHY
The procedure has been fully described in the
previous WFUMB guidelines on liver elastography
(Ferraioli et al. 2015). The strengths of the TE approach
are that it is widely available and a point-of-care tech-
nique. Weaknesses are the lack of gray-scale image
guidance to determine where the measurement is being
obtained, inability to visualize and avoid large vessels
and masses at the site of measurement (although these
may be generally identified on the time-motion and
A-mode), the need for recalibration of the spring in the
device at 6- to 12-mo intervals (depending on the type of
probe), decreased applicability in cases of obesity and
inability to use it in patients with ascites.ARFI-BASED TECHNIQUES
The procedure has been fully described in the previ-
ous guidelines (Barr et al. 2016b). These are listed in
Table 2.
WFUMB Update  G. FERRAIOLI et al. 2423Although most vendors allow measurements to
8 cm from the transducer, measurement accuracy
decreases below 6 cm from the transducer because of
attenuation of the ARFI pulse.
The literature suggests that 10 measurements
should be obtained for p-SWE, and the median value
reported. Several studies have indicated that an IQR/
median (M) 30% (measurements in kPa) improves
accuracy in staging liver fibrosis. Recent literature sug-
gests that a smaller number of measurements may be
accurate (Fang et al. 2018; Ferraioli et al. 2016a); how-
ever, at this time there is not enough literature to support
this suggestion. The energy deposition of the ARFI push
pulse for U.S. Food and Drug Administration (FDA)-
approved vendor systems is within current FDA diagnos-
tic limits for livers in adults. Off-label use for other
organs and for use during and immediately after the use
of US contrast materials should be avoided until further
investigated (Cui et al. 2014).
In 2-D SWE, a larger field of view (FOV) is placed
where the elastogram will be obtained. Within that FOV,
regions of interest (ROIs) can be placed to obtain the
stiffness value. As opposed to p-SWE, the ROI size can
be changed. If possible, the ROI should be placed near
the center of the FOV, as there are often errors at the bor-
ders of the FOV. Most vendors provide the average and
the standard deviation of the stiffness values from the
pixels in the ROI, and some of them provide the mini-
mum and maximum stiffness values as well. The mean
value should be used. The standard deviation within the
ROI reports the variability of the pixel measurements
within the ROI and is not a measure of the quality of the
measurement.
Not enough studies have been performed to provide
recommendations, but several studies using 2-D SWE
have used three or five measurements if the system has a
quality measure that confirms the area of measurement
has high-quality shear waves (Dietrich et al. 2017a).
Most vendors with 2-D SWE may allow the placement
of many ROIs within the elastogram FOV. This is dis-
couraged, because if there is an error in that image, the
error is reproduced in all the measurements from that
image.STRAIN ELASTOGRAPHY
There is no significant change from previous
WFUMB liver elastography guidelines (Table 2)
(Ferraioli et al. 2015).
A limited study using combinational elastogra-
phy, the combined use of strain and shear wave imag-
ing with a single machine, might increase accuracy in
the diagnosis of liver fibrosis and inflammation (Yada
et al. 2017a, 2017b). Data mining, which combinesSE and serologic tests, is reported to be the novel
approach (Yada et al. 2014). In a meta-analysis
(Kobayashi et al. 2015) of 15 studies with 1626
patients, SE was found not to have high accuracy for
any cutoff stage of fibrosis.
REPRODUCIBILITY
Shear wave elastography techniques have excellent
reproducibility, provided the recommendations of the
manufacturer or expert recommendations are followed.
For all systems, intra-observer reproducibility assessed
with the intra-class correlation coefficient (ICC) was
>0.90, and inter-observer reproducibility was >0.80
(Boursier et al. 2008a; Fang et al. 2017; Ferraioli et al.
2012; Fraquelli et al. 2007; Garcovich et al. 2017; Hud-
son et al. 2013).
Factors that influence the reproducibility of the
measurement are similar across the different techniques
and are related to the operator’s experience and to fac-
tors dependent on the subject being examined. A learn-
ing curve has been consistently observed not only for TE
(Boursier et al. 2008b), but also for p-SWE
(Fraquelli et al. 2016) and 2-D SWE (Ferraioli et al.
2012; Hudson et al. 2013; Woo et al. 2015), with higher
reproducibility achieved by expert operators.
Inter-observer variability increases with higher liver
fibrosis stages (Boursier et al. 2008a; Fraquelli et al.
2007; Vuppalanchi et al. 2018) and in overweight or
obese patients (Boursier et al. 2008a; Fraquelli et al.
2007). Patient position and respiration phase can affect
the results, and variability is decreased by using stan-
dardization.
CONFOUNDING FACTORS AND LIMITATIONS
Although liver fibrosis is the main determinant of
liver stiffness, a number of factors have been found to
influence LSM, often resulting in a false-positive diag-
nosis of advanced fibrosis or cirrhosis. Clinicians should
be aware of these confounding factors and avoid using
liver elastography in such situations. Although most of
the studies were conducted using TE for historical rea-
sons, studies using p-SWE or 2-D SWE almost always
produced similar effects, suggesting that the same con-
founders should affect all techniques similarly. Con-
founding factors were already reported in the previous
guidelines (Barr et al. 2016b; Dietrich et al. 2017a; Fer-
raioli et al. 2015). Details on the published studies are
available in Supplement 1 (online only). Liver steatosis
causes attenuation of the ARFI pulse and can lead to
more variability in the measurements, although theoreti-
cally it should not affect the SWS, based on current
ARFI methods in clinical use, even though some reports
have indicated that livers with steatosis have increased
2424 Ultrasound in Medicine & Biology Volume 44, Number 12, 2018viscoelasticity, which can also affect SWS. Published
studies have conflicting results.
RECOMMENDATION 2: The impact of hepatic
steatosis on liver stiffness is uncertain. Clinicians
should exercise caution when interpreting liver stiff-
ness results in patients with severe steatosis and obe-
sity. (LoE 5, GoR C) (10,0,0)VIRAL HEPATITIS
Hepatitis B
The performance of transient elastography in
chronic hepatitis B was described in the last WFUMB
guidelines (Ferraioli et al. 2015). Since then, 2-D SWE
(Leung et al. 2013; Zeng et al. 2017) and p-SWE
(Hu et al. 2017; Kim et al. 2016; Su et al. 2018) have
also been evaluated against liver histology in patients
with chronic hepatitis B. Overall, studies have indicated
similar diagnostic accuracy across different machines.
The accuracy is generally good for the diagnosis of
bridging fibrosis and cirrhosis, and it is modest for
milder degrees of fibrosis. Two-dimensional SWE and
p-SWE also have lower failure rates, especially among
obese patients. As currently available antiviral drugs are
tolerable and efficacious, the decision to start antiviral
therapy can in most cases be made based on serum ala-
nine aminotransferase and hepatitis B virus DNA levels,
as well as non-invasive tests of fibrosis (European Asso-
ciation for the Study of the Liver [EASL] 2017; Terrault
et al. 2018). Patients with liver stiffness values sugges-
tive of cirrhosis would need surveillance for hepatocellu-
lar carcinoma and varices. Liver biopsy is now rarely
required outside the research setting.
A high serum alanine aminotransferase (ALT)
level is one of the major confounding factors for liver
stiffness measurement (see Supplement 1 for details).
Even patients with mild to moderate ALT elevation
to one to five times the upper limit of normal have
higher liver stiffness than those with normal ALT
levels (Chan et al. 2009). Oral nucleos(t)ide ana-
logues effectively suppress hepatic necroinflammation
and lead to ALT normalization in the majority of
patients with chronic hepatitis B (Wong et al. 2009).
Studies have consistently found that patients can
have a significant reduction in liver stiffness during
nuleos(t)ide analogue treatment even when there is
little or no improvement in histologic fibrosis (Liang
et al. 2018; Wong et al. 2011). The optimal cutoffs
for fibrosis and cirrhosis in treated patients are likely
to be lower than those in untreated patients, but need
to be defined in future studies. In addition, although
long-term nucleos(t)ide analogue treatment can
reverse histologic cirrhosis (Marcellin et al. 2013),
the risk of hepatocellular carcinoma in such patientsis still higher than in those who never had cirrhosis
(Wong et al. 2013). On the other hand, worsening of
portal hypertension and new development of varices
should be uncommon during nucleos(t)ide analogue
treatment, though the experience is limited to small-
cohort studies (Lampertico et al. 2015). Until further
data are available, it is premature to recommend a
change in surveillance strategies in cirrhotic patients
treated with nucleos(t)ide analogues based on changes
in liver stiffness.
RECOMMENDATION 3: SWE is useful to
exclude significant fibrosis and diagnose cirrhosis in
patients with untreated chronic hepatitis B. (LoE 1a,
GoR A) (10,0,0)
RECOMMENDATION 4: Liver stiffness usually
decreases during antiviral treatment with analogues.
Screening for hepatocellular carcinoma and portal
hypertension should continue despite decrease liver
stiffness in patients with advanced disease (LoE 1b,
GoR A) (10,0,0)
Hepatitis C
The current recommendations for treatment of HCV
vary significantly between countries and health care sys-
tems, according to the availability of therapy. In the
absence of universal access to direct-acting antiviral
agents (DAAs), as a consequence of high cost, different
countries have implemented strategies to prioritize
patients for treatment based on disease stage. In that
respect, SWE can be used as the first-line investigation
for the prioritization of HCV patients for DAAs (Die-
trich et al. 2017b; EASL 2015a, 2015b; EASLALEH
2015). The most important endpoint is the presence of
cirrhosis as these patients are still at risk (although much
lower) of developing liver-related complications, such
as portal hypertension and hepatocellular carcinoma
(HCC) (Di Marco et al. 2016; Nahon et al. 2017; van der
Meer et al. 2017; Yada et al. 2016), after HCV eradica-
tion. Thus, they require regular follow-up.
RECOMMENDATION 5: SWE is the preferred
method as the first-line assessment for the severity of
liver fibrosis in untreated patients with chronic viral
hepatitis C. It is useful to rule out advanced disease.
(LoE 1a, GoR A) (10,0,0)
Role of elastography during antiviral treatment
(monitoring)
Most data available on the usefulness of liver stiff-
ness monitoring during antiviral therapy have been
obtained with TE. Monitoring of liver stiffness during
antiviral treatment with interferon-based therapies has
not been considered clinically meaningful (Hezode et al.
2011; Yada et al. 2014) and has not been recommended
by guidelines (Ferraioli et al. 2015). Data in patients
WFUMB Update  G. FERRAIOLI et al. 2425treated with DAAs suggest that liver stiffness rapidly
declines during treatment, even in patients with
advanced fibrosis and cirrhosis (Chan et al. 2018; Fac-
ciorusso et al. 2018; Knop et al. 2016; Ogasawara et al.
2018; Persico et al. 2018; Pons et al. 2017; Sporea et al.
2017). This decline appears to reflect the reduction in
liver inflammation, like an effect of HCV eradication.
However, given the short duration of treatment with
DAAs (12 wk) and the high sustained virologic response
(SVR) rates (>90%), monitoring of liver stiffness during
treatment does not appear clinically relevant.
Role of elastography after treatment (monitoring in
follow-up)
Although it is tempting to monitor liver stiffness, in
cirrhotic patients after SVR, based on the currently avail-
able evidence, liver stiffness decrease cannot be used as
a surrogate of cirrhosis regression. Therefore, no recom-
mendation can be made at this stage on cutoffs and the
time interval to identify cirrhosis regression.
A detailed discussion is presented in Supplement 2
(online only).
RECOMMENDATION 6: Liver stiffness
decreases significantly after sustained virological
response to treatment with interferon-based thera-
pies or direct-acting antiviral agents. However, liver
stiffness cannot be used to stage liver fibrosis or rule
out cirrhosis, given the loss of accuracy of cutoffs
defined in viremic patients. Screening for hepatocel-
lular carcinoma and portal hypertension should con-
tinue despite decrease in liver stiffness in patients
with advanced disease. (LoE 1b, GoR A) (10,0,0)
NON-ALCOHOLIC FATTY LIVER DISEASE/
NON-ALCOHOLIC STEATOHEPATITIS
Non-alcoholic fatty liver disease (NAFLD) is
becoming the most common cause of chronic liver dis-
ease and a risk factor for HCC (Dyson et al. 2014).
Transient elastography
Several studies have reported the performance of
TE in the assessment of liver fibrosis in NAFLD
patients. A recent large meta-analysis (Xiao et al. 2017)
has reported that, with the M probe, the cutoff for
advanced fibrosis ranged from 7.6 to 9 kPa in 14 studies
including 2697 patients, with 83% to 89% sensitivity
and 77% to 78% specificity. For the XL probe, the cutoff
ranged from 5.7 to 9.3 kPa in three studies including 579
patients, with 75% sensitivity and 74% specificity. In a
multicenter study (Petta et al. 2015) of NAFLD patients
with liver biopsy data, the cutoff values were 6.9 kPa for
F  2 and 8.4 kPa for F  3. In this study, the presence
of severe liver steatosis was associated with higherLSMs in patients with low-grade fibrosis, leading to the
overestimation of liver fibrosis. Therefore, in NAFLD
patients, severe steatosis could be a confounding factor
(Petta et al. 2015).
In almost all studies, obesity was the major reason
for unreliable LSMs; however, the use of the M probe
seems the major limitation, leading to higher LSMs and
a higher false-positive rate. This limitation is somewhat
overcome by using the XL probe (Friedrich-Rust et al.
2010; Wong et al. 2010). It has been reported that the
XL probe gives cutoff values 1.52 kPa lower than that
obtained with the M probe. In a study that compared the
M and XL probes (Wong et al. 2012) on 155 patients,
the measurements with M and XL probes correlated well
with each other, r = 0.95, but with the XL probe, the
LSMs were lower.
It has therefore been suggested that different cutoff
values be used for different probes. For the M probe,
with a 90% sensitivity and specificity to rule in or rule
out significant fibrosis, advanced fibrosis and cirrhosis,
the cutoff values were 5.8 and 9.0 kPa, 7.9 and 9.6 kPa,
and 10.3 and 11.5 kPa, respectively (Wong et al. 2010).
For the XL probe, with a 90% sensitivity and specificity
to rule-in or rule-out significant fibrosis, advanced fibro-
sis and cirrhosis, the cutoff values were 4.8 and 8.2 kPa,
5.7 and 9.3 kPa and 7.2 and 11.0 kPa, respectively
(Wong et al. 2012).
Point shear wave elastography
Few studies have addressed the value of p-SWE
for liver fibrosis in NAFLD/non-alcoholic steatohepati-
tis (NASH) (Cassinotto et al. 2013; Fierbinteanu Brati-
cevici et al. 2013; Friedrich-Rust et al. 2012; Liu et al.
2015b; Osaki et al. 2010; Yoneda et al. 2010). The
most recent is a systematic review with meta-analysis,
but the article did not provide the optimal cutoff values,
and only reported that the p-SWE technique had
good performance (area under the receiver operating
characteristic curve [AUROC] = 0.89, sensitivity = 80%)
(Liu et al. 2015b).
2-D shear wave elastography
Three studies available in the literature report the
performance of 2-D SWE (Cassinotto et al. 2016; Herr-
mann et al. 2018; Zheng et al. 2015). The most recent is a
meta-analysis with individual patient data that proposed a
cutoff value for diagnosing significant fibrosis (F  2):
>7.1 kPa (AUROC = 0.85) (Herrmann et al. 2018).
One study compared three elastographic methods
(TE, p-SWE and 2-D SWE) in NAFLD patients (Cassi-
notto et al. 2014). For significant fibrosis , 2-D SWE was
superior to p-SWE, and for severe fibrosis and cirrhosis,
all methods had similar performance. In a large meta-
analysis (Xiao et al. 2017), 2-D SWE had higher
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scores in staging fibrosis.
RECOMMENDATION 7: SWE can be used for
liver stiffness assessment in NAFLD patients to rule
out advanced fibrosis and select patients for further
assessment. (LoE 1a, GoR A) (10,0,0)ALCOHOLIC LIVER DISEASE
Chronic, excessive alcohol consumption can lead to
a large spectrum of damage, from liver steatosis to liver
cirrhosis (MacSween and Burt 1986). The risk of devel-
oping cirrhosis starts with 30 g ethanol/d and increases
with increasing daily intake. Also, drinking multiple dif-
ferent alcoholic beverages can increase the risk of devel-
oping ALD (Bellentani et al. 1997). Other studies have
found that the risk ratio increases significantly with
daily consumption of 2040 g ethanol/d in women and
>80 g ethanol/d in men (Stewart and Day 2011;
O’Shea et al. 2010).Assessment of liver fibrosis
It is important to identify patients with advanced
fibrosis who are at risk of developing decompensated
liver cirrhosis and HCC. Unfortunately, there are few
studies published in the literature.Transient elastography
There are several studies that reported that TE can
be used in patients with ALD, with good performance;
however, they report different cutoff values (Anastasiou
et al. 2010; Bardou-Jacquet et al. 2013; Boursier et al.
2009; de Ledinghen et al. 2012b; Dolman et al. 2013;
Janssens et al. 2010; Kim et al. 2009; Lannerstedt et al.
2013; Lemoine et al. 2008; Mueller et al. 2010; Nahon
et al. 2008; Nguyen-Khac et al. 2008; Thiele et al. 2016,
2018; Voican et al. 2017). A Cochrane review summa-
rized these studies (Pavlov et al. 2015) and reported that
for diagnosing significant fibrosis, the optimal cutoff
value were around 7.5 kPa, with 94% sensitivity and
89% specificity. For severe fibrosis, a cutoff value of 9.5
kPa (range: 811 kPa) gave 92% sensitivity and 70%
specificity. For liver cirrhosis, the optimal cutoff value
was 12.5 kPa, with 95% sensitivity and 71% specificity
(Pavlov et al. 2016).Point shear wave elastography
There are three studies in the literature on liver
fibrosis assessment with p-SWE. One study
(Liu et al. 2015a) reported only that the correlation
between p-SWE and liver biopsy is good (r = 0.71). The
other two studies (Kiani et al. 2016; Zhang et al. 2015),
in which liver biopsy was also performed, gave differentcutoff values. This may have occurred because the two
studies had smaller and different numbers of patients.
2-D shear wave elastography
There are limited studies in the literature on the use
of 2-D SWE in ALD (Thiele et al. 2016).
When is the best time to assess liver fibrosis in ALD
patients?
Four studies reported that liver stiffness decreases
significantly after patients stopped alcohol abuse (Bar-
dou-Jacquet et al. 2013; Gelsi et al. 2011; Mueller et al.
2010; Trabut et al. 2012). Another study found that it is
better to scan the patients when they have AST values
<100 U/L (Mueller et al. 2015). Measurements are more
accurate if performed after a period of abstinence (Bar-
dou-Jacquet et al. 2013; Gianni et al. 2017)
Recommendation 8: SWE can be used for liver
stiffness assessment in patients with ALD to rule out
advanced disease. Caution is needed in patients with
ongoing alcohol abuse or with acute alcoholic hepati-
tis. (LoE 2a, GoE B) (10,0,0)
OTHER ETIOLOGIES
Autoimmune hepatitis (AIH) is a chronic inflamma-
tory liver disease of unknown origin. Hepatic fibrosis
may progress despite immunosuppressive treatment
(Manns et al. 2010). Approximately one-third of patients
already have established cirrhosis at diagnosis. Accord-
ing to the International Autoimmune Hepatitis Group,
the diagnosis of AIH is based on a combination of bio-
chemical, immunologic and histologic features and the
exclusion of viral hepatitis (Hennes et al. 2008). No gen-
erally accepted characteristic imaging features of AIH
have been described.
AIH patients tend to have higher LSM cutoff values
using TE (Abdalla et al. 2009; Fitzpatrick et al. 2013;
Guo et al. 2017; Sagir et al. 2008; Wang et al. 2011; Xu
et al. 2017b), p-SWE (Bota et al. 2013; Efe et al. 2015;
Righi et al. 2012) and 2-D SWE (Sun et al. 2016), com-
pared with patients with HCV and other etiologies. This
could be explained by concomitant inflammatory activ-
ity, which can increase liver stiffness. TE can predict the
grade of fibrosis in treated AIH patients (Anastasiou
et al. 2016; Hartl et al. 2016; Sporea et al. 2013), with
better results after 6 mo than at earlier time points
(Hartl et al. 2016).
There is some preliminary evidence suggesting that
primary biliary cirrhosis (PBC) and primary sclerosing
cholangitis (PSC) have prognostic significance for LSM
(Corpechot et al. 2012, 2014).
There is insufficient evidence to make a recommen-
dation on the use of SWE for liver stiffness assessment
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liver diseases.CIRRHOSIS AND ITS COMPLICATIONS
For the diagnosis of cirrhosis there are no major
changes from the previous guidelines (Ferraioli et al. 2015).
In patients with advanced chronic liver disease/compen-
sated cirrhosis, LSM is significantly and positively corre-
lated with the hepatic venous pressure gradient (HVPG,
“gold standard” method for portal hypertension in cirrho-
sis).
Most data available concern TE. With this tech-
nique, LSM and HVPG yield a correlation coefficient of
0.550.86 (Berzigotti 2017). Even if an accurate estima-
tion of the HVPG value cannot be achieved using LSM,
LSM accurately discriminates between patients with and
without clinically significant portal hypertension (CSPH,
defined as HVPG 10 mm Hg, threshold for the appear-
ance of complications); the summary AUROC is 0.93
according to a meta-analysis (You et al. 2017). It should
be underlined that most of the patients included in the
studies that correlated HVPG with LSMs had viral or
alcoholic cirrhosis, and evidence regarding other etiolo-
gies remains limited. In untreated viral cirrhosis, LSM
values >2025 kPa are highly specific for CSPH
(You et al. 2017). Values of LSM >20 kPa remain asso-
ciated with the presence of CSPH in patients with HCV-
related cirrhosis who achieved SVR with DAAs
(Lens et al. 2017); importantly, the decrease in LSM to
lower values after SVR does not exclude CSPH, and
therefore, clinical follow-up should be continued irre-
spective of the value of LSM in this population
(Lens et al. 2017).
High LSM values are also significantly associated
with the presence and size of gastroesophageal varices,
with summary AUROCs of 0.780.84 (Berzigotti 2017).
Platelet count and spleen size significantly improve the
prediction of varices, obtained by LSM alone
(Berzigotti et al. 2013). It has been reported that com-
pensated patients with values of LSM <20 kPa and nor-
mal platelet counts (>150 G/L) bear a very low risk of
varices requiring treatment (large varices or varices with
red signs) (Abraldes et al. 2016). These criteria have
been recommended by the Baveno VI consensus confer-
ence on portal hypertension as a rule, to eliminate unnec-
essary endoscopies (de Franchis and Baveno 2015).
Since the publication of the recommendation, several
studies have confirmed that these criteria are safe
(03% of varices needing treatment are missed), but
very conservative, allowing endoscopy to be spared in
only 15% to 30% of patients with compensated cirrhosis
(Marot et al. 2017). Expanded criteria have recently
been proposed by a multicentric consortium; an LSM<25 kPa and platelet count >110 g/L might be used
safely, eliminating a larger proportion of endoscopies
(32% vs. 14%) (Augustin et al. 2017).
Data regarding LSMs by p-SWE and 2-D SWE in
this field remain limited.
Point SWE has been used in three studies address-
ing the diagnosis of CSPH (Attia et al. 2015; Salzl et al.
2014; Takuma et al. 2016b) and reporting excellent
applicability and very good diagnostic accuracy
(AUROC: 0.820.90). Point SWE has been used in a
few studies addressing the diagnosis and severity of
esophageal varices. Liver stiffness was higher in patients
with esophageal varices of any size and was even higher
in patients with large varices (Attia et al. 2015; Salzl
et al. 2014), However, reliable cutoffs are not available
yet. No strong recommendation regarding the cutoffs to
be used can be made because of the limited evidence.
Two-dimensional SWE has been tested for the diag-
nosis of CSPH in four studies and a further small series
(Choi et al. 2014; Elkrief et al. 2015; Jansen et al. 2016a;
Kim et al. 2015; Procopet et al. 2015). The accuracy of
the method was reliable in all of the published studies
(AUROC: 0.800.92). Two studies performed a head-
to-head comparison between LSMs obtained by TE and
2-D SWE (Elkrief et al. 2015; Procopet et al. 2015). TE
was less applicable, and both techniques had similar
accuracy for the diagnosis of CSPH.
In summary, in the available studies, the applicabil-
ity and diagnostic accuracy of both techniques closely
resemble those of TE (for CSPH p-SWE: AUROC
0.820.90; 2-D SWE: AUROC 0.800.92) (Berzi-
gotti 2017). Cutoffs are, however, not yet well defined
and vary across studies (pSWE: 2.172.58 m/s; 2-D
SWE: 15.224.5 kPa). Similar considerations apply to
the diagnosis of varices.
One study compared TEwith p-SWE (Salzl et al. 2014),
and two studies concomitantly evaluated TE and 2-D
SWE (Elkrief et al. 2015; Procopet et al. 2015), report-
ing similar accuracy for the detection of CSPH.
Because of the limited evidence to date, non-invasive
criteria to rule out varices based on p-SWE or 2-D
SWE cannot yet be recommended.
Spleen stiffness measurement (SSM) has been pro-
posed as an additional parameter potentially better corre-
lating with portal pressure, irrespective of its cause. Data
in cirrhosis are conflicting. A meta-analysis of 16 studies
(using either TE, p-SWE or 2-D SWE) pointed to the
superiority of this method (Ma et al. 2016), but the appli-
cability of TE and 2-D SWE in this setting (about 70%)
and the heterogeneity of the populations assessed do not
allow recommendations on its use in clinical practice.
Recent studies using TE found that LS was more accu-
rate than spleen stiffness (SS) for the diagnosis of CSPH
(AUROCs of 0.95 vs. 0.85 [Zykus et al. 2015]; 0.78 vs.
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SS measurement (SSM) using pSWE could better predict
the presence of varices and high-risk varices compared
with LS. For example, one study including 340 cirrhotic
patients and 16 healthy volunteers with invasive endos-
copy as the reference standard found that a shear wave
velocity cutoff value of 3.30 m/s identified high-risk
esophageal varices, with a negative predictive value,
sensitivity and accuracy of 0.994, 0.989 and 0.721,
respectively (Takuma et al. 2013). In another study,
SSM cutoff values of 3.36 and 3.51 m/s identified
patients with esophageal varices and high-risk esophageal
varices, respectively, with negative predictive values of
96.6% and 97.4%, respectively (Dietrich et al. 2017a).
Several additional studies have found SSM to be predic-
tive of esophageal varices (Sigrist et al. 2017). LSMs
obtained with 2-D SWE are higher in patients with esoph-
ageal varices of any size and are further increased in
patients with large varices. However, reliable cutoff val-
ues are not available yet. No strong recommendation
regarding the cutoff values for 2-D SWE can be given,
and further evidence is needed.
Sequential LSMs and SSMs using 2-D SWE have
been recently proposed to improve the selection of
patients requiring endoscopy (Jansen et al. 2016b).
RECOMMENDATION 9: SWE has high diag-
nostic accuracy for detecting cirrhosis, better at rul-
ing out (high negative predictive value >90%) than
ruling in. (LoE 1a, GoR A) (10,0,0)
Clinical decompensation and other clinical endpoints
Liver stiffness measurements obtained with TE are
able to predict liver-related events (clinical complica-
tions, HCC and liver-related death) as confirmed in a
meta-analysis (Singh et al. 2013). As for clinical decom-
pensation, LSMs 21 kPa were as accurate as HVPG
10 mm Hg in one study (Robic et al. 2011). LSM by 2-
D SWE also predicted clinical decompensation in one
study (Grgurevic et al. 2015). For p-SWE, data on this
aspect are still lacking.
Spleen stiffness measurements predicted clinical decom-
pensation in one study using TE (Colecchia et al. 2014) and
one study using 2-D SWE (Grgurevic et al. 2015). In
one study using p-SWE, SSM predicted variceal bleed-
ing (Takuma et al. 2016a).
Changes in LSMs do not correlate with changes in
HVPG in patients undergoing therapy with non-selective
beta blockers (Reiberger et al. 2012). Yearly LSM to fol-
low up patients with portal hypertension has been sug-
gested (de Franchis and Baveno 2015) but has not been
validated yet.
RECOMMENDATION 10: Liver stiffness meas-
urements of TE >20 kPa can be used to identify
patients likely bearing clinically significant portalhypertension (HVPG 10 mm Hg). (LoE 2b, GoR B)
(10,0,0)
RECOMMENDATION 11: Liver stiffness mea-
surement using TE<2025 kPa combined with plate-
let count >110150£ 106/mL is useful in ruling out
varices needing treatment. (LoE 2b, GoR B) (10,0,0)
RECOMMENDATION 12: Liver stiffness mea-
surement holds prognostic value in compensated cir-
rhosis, and the higher the value, the higher is the risk
of clinical complications. (LoE 2b, GoR B) (10,0,0)PEDIATRICS
Preliminary data on SWE techniques including TE,
p-SWE and 2-D SWE have been published for the evalu-
ation and follow-up of liver fibrosis in children (Behairy
Bel et al. 2016; Belei et al. 2016; Chen et al. 2016a,
2016b; Desai et al. 2016; Ferraioli et al. 2017; Franchi-
Abella et al. 2016; Garcovich et al. 2017; Gersak et al.
2016; Ghaffar et al. 2016; Hanquinet et al. 2016; Hatta-
poglu et al. 2016; Jung et al. 2017; Kamble et al. 2017;
Lodwick et al. 2017; Mann et al. 2016; Ozkan et al.
2017; Phelps et al. 2017; Raizner et al. 2017; Tokuhara
et al. 2016; Trout et al. 2016; Yoon et al. 2017). Normal
values in liver elasticity measured by SE in healthy
infants and children were reported (Selmi et al. 2014). In
comparison to adult patients, different factors are
encountered in children. The age, size and specific anat-
omy of the patients result in different probe diameters
and eventually different examination techniques, includ-
ing sedation, resulting in different cutoff values. This
means that the cooperation of children (including breath-
holding) and cooperation of parents have to be taken into
account. There is a variety of specific pediatric etiologies
of diseases, with different influencing factors as well. In
many diseases, the cutoff values are not as precisely
known as they should be; therefore, individual follow-up
examination plays a major role.Examination technique and normal values
The Fibroscan S probe (tip diameter of 5 mm com-
pared with 7 mm for the M probe) has been adapted to
the needs of children. TE is technically feasible and reli-
able in children of all age groups, but less successful in
children <6 y old. Successful LSMs are even rarer in
children <24 mo. The current recommendations from
the manufacturer suggest using the S1 probe for thorax
diameter <45 cm, S2 for 4575 cm and M probe for
thorax diameter >75 cm. The median and upper limit of
normal values increase significantly with age (Engel-
mann et al. 2012; Lewindon et al. 2016; Tokuhara et al.
2016). The values were 4.4, 4.7 and 5.1 kPa in children
05, 611 and 1218 y of age (p = 0.001), respectively,
while the IQR decreased with age (0.8 0.7, and 0.6 kPa)
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ited lower median LSMs than males (4.7 vs. 5.6 kPa,
p < 0.005) (Engelmann et al. 2012), but no differences
in other studies (Goldschmidt et al. 2013; Lewindon
et al. 2016).
Studies with a smaller number of patients, but with
results similar to those obtained with TE data, have been
obtained using p-SWE (Bailey et al. 2017; Trout et al.
2016). In 132 children, the mean value of p-SWE meas-
urements was 1.16 m/s (standard deviation: §0.14 m/s)
(Eiler et al. 2012). Point SWE was feasible in children of
any age (Hanquinet et al. 2013; Matos et al. 2014).
It has been found that three acquisitions of a 2-D
SWE technique can be enough for assessing SWSs in
children >6 y, regardless of breathing status or hepatic
pathology. More acquisitions are recommended for chil-
dren <5 y, during free breathing (Jung et al. 2017; Shin
et al. 2016).
Published evidence obtained with SE in children is
scarce and contradictory (Schenk et al. 2014a, 2014b;
Selmi et al. 2014).
Staging of fibrosis
The correlation of LSM with fibrosis stages has
been examined in chronic liver diseases of different
etiologies, with promising results (Behairy Bel
et al. 2016). It must be taken into account that each
liver disease may present different cutoff values when
interpreting LSM for assessing fibrosis and may also
depend on the severity of inflammation. General anes-
thesia and food intake also significantly increase liver
stiffness in healthy children (de Ledinghen et al. 2007;
Lee et al. 2013; Raizner et al. 2017). No general con-
clusions have been drawn so far to allow staging of
fibrosis.
Point SWE and 2-D SWE techniques may have
advantages in differentiating different stages of fibrosis
(Fontanilla et al. 2014; Marginean and Marginean 2012;
Ozkan et al. 2017; Pinto et al. 2014; Tomita et al. 2013).
Liver diseases associated with cystic fibrosis have been
examined using p-SWE (Canas et al. 2015). With TE as
a reference method, the sensitivity of p-SWE for detect-
ing fibrosis F1 was 71.4%, for F2 77.8%, for F3 62.5%
and for F4 71.4%. The sensitivity of 2-D SWE for
detecting F1 was 92.8%, for F2 83.3%, for F3 87.5%
and for F4 85.7%. Significant correlations were found
between TE and 2-D SWE (k correlation factor = 0.843,
p = 0.001) (Belei et al. 2016).
Follow-up examinations
Pediatric diseases are rare; therefore, large studies
presenting reliable data in a large cohort of patients are
lacking. Follow-up examinations are recommended for
pediatric patients with liver diseases to screen forcomplications including liver cirrhosis, portal hyperten-
sion and malignant transformation (Yoon et al. 2017). In
patients with biliary atresia, the time for LSMs after the
Kasai procedure for liver transplantation is important
(Hanquinet et al. 2015, 2016) and promising (Chen et al.
2016b; Chongsrisawat et al. 2011). Follow-up examina-
tions are generally necessary after liver transplantation
(Tomita et al. 2013).
The combination of TE with pediatric NAFLD fibro-
sis index has been examined in children with NAFLD to
assess the grade of fibrosis (Alkhouri et al. 2013). No rec-
ommendation can be given so far. CAP (Sasso et al. 2010)
allows estimation of liver steatosis in pediatric (obese)
patients (Desai et al. 2016). No recommendation can be
given so far.
RECOMMENDATION 13: There is insufficient
evidence to make a recommendation on the use of
SWE for liver stiffness assessment in pediatric
patients. (LoE 5, GoR D)(10,0,0)FOCAL LIVER LESIONS
Diagnosis of focal liver lesions (FLLs) is needed to
identify patients with malignant liver disease, to deter-
mine the correct management and to differentiate these
patients from those with benign and insignificant pathol-
ogy. For many years, contrast-enhanced computed
tomography and MR scans, and more recently contrast-
enhanced ultrasound (CEUS), have shown their value
and ability to provide correct diagnoses without the
requirement for surgery or biopsy. Currently, the use of
elastography for characterization of FLLs remains inves-
tigational. It is hoped that elastography may supplement
imaging to give more specific diagnoses in selected
patients.
Although several reports document that malignant
lesions are more likely stiffer than benign lesions, there
is significant overlap. Both benign and malignant lesions
can be soft or stiff compared with normal liver. In addi-
tion, the stiffness of the liver varies significantly with
fibrosis. So, in any given patient elastography is not able
to characterize liver lesions with significant accuracy for
clinical use (Omichi et al. 2015; Yu and Wilson 2011).
At present, sonoelastography is not recommended for
characterization of FLLs (Barr et al. 2016b). However,
there are a few situations in which FLL stiffness may be
of benefit, for example, focal nodular hyperplasia versus
hepatic adenoma and in HCC cases (see Supplement 3,
online only).
RECOMMENDATION 14: There is insufficient
evidence to make a recommendation on the use of
SWE for differentiation between benign and malig-
nant lesions and characterization of focal liver
lesions. (LoE 5, GoR D) (10,0,0)
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Non-alcoholic fatty liver disease is becoming the
leading cause of chronic liver disease worldwide. The
term comprises a range of conditions, from simple stea-
tosis to NASH. This latter may evolve into cirrhosis and
its complications.
Even though liver biopsy is considered the gold
standard for steatosis grading, the procedure cannot be
used to screen a large population and is unsuitable for
monitoring changes that may occur over short periods.
The CAP has been proposed for non-invasive grad-
ing liver steatosis (Sasso et al. 2010).
Failure
In a prospective study of 5323 examinations per-
formed in patients with chronic liver diseases with the M
probe, the CAP failure rate (defined as no results) was
7.7% (de Ledinghen et al. 2014). The factors indepen-
dently associated with CAP failure were female, over-
weight or obesity and metabolic syndrome, consistent
with those already reported for liver stiffness
(Castera et al. 2010). In another recent study based on
1696 examinations, in 992 NAFLD patients, in whom
both M and XL probes were used depending on the skin-
to-liver capsule distance, the failure rate was lower:
3.2% (Vuppalanchi et al. 2018).
Reproducibility
Reproducibility has been assessed in two indepen-
dent studies using the M probe (Ferraioli et al. 2014b;
Recio et al. 2013). The concordance between observers
was excellent, 0.82 (95% CI: 0.780.85)
(Pineda et al. 2009) and 0.84 (95% CI: 0.770.88)
(Recio et al. 2013), respectively. However, the agree-
ment between raters decreased for body mass index
(BMI) >30 kg/m2 (0.65) and for CAP values
<240 dB/m (0.44) (Ferraioli et al. 2014b).
A recent study of 838 NAFLD patients (BMI: 33.6 §
6.5 kg/m2), in whom both the M and XL probes were
used, found that the intra-observer and inter-observer cor-
relations were high overall: r = 0.82 and r = 0.70, respec-
tively. However, the correlation decreased with the XL
probe (M probe vs. the XL probe: intra-observer correla-
tion: r = 0.85 vs. 0.75, p = 0.0003; inter-observer correla-
tion r = 0.64 vs. 0.68, p = 0.71) (Vuppalanchi et al. 2018).
Quality criteria
In the absence of specific quality criteria provided
by the manufacturer, investigators have used those used
for LSM. Recently, an international multicenter study,
including 754 consecutive patients, in whom CAP was
measured with the M probe before liver biopsy, reportedthat the accuracy of CAP declined when its IQR was
>40 dB/m (with an AUROC for fatty liver of 0.77 vs.
0.90 in patients with IQR <40 dB/m, p = 0.004)
(Wong et al. 2017). The authors suggested that an IQR
<40 dB/m could be used as a quality criterion. These
findings require further external validation before any
recommendation can be made.
Accuracy and cutoff values (comparison with histologic
steatosis grade)
Several studies have found that CAP values corre-
late with the histologic grades of steatosis; however,
there is a large overlap between adjacent grades. Cut-
off values varied between studies; however, the cutoff
value associated with significant steatosis (>33% of
hepatocytes) was almost always around 250 dB
(Castera 2015). A summary table on the performance
of CAP for grading steatosis has recently been pub-
lished (Castera 2015). CAP values are not influenced
by liver fibrosis and cirrhosis (de Ledinghen et al.
2012a; Ferraioli et al. 2014a; Kumar et al. 2013; Myers
et al. 2012; Sasso et al. 2012).
In a recent individual data meta-analysis based on
19 studies and 2735 patients (hepatitis B 37%, hepatitis
C 36%, NAFLD/NASH 20%, other etiologies 7%), 1391
patients had S0 grade, 754 S1 grade, 427 S2 grade and
163 S3 grade (Karlas et al. 2017). Optimal cutoff values
and 95% confidence intervals were 248 (237261) dB/
m for S >0, 268 (257284) dB/m for S >1 and 280
(268294) dB/m for S >2. AUROCs were 0.82
(0.810.84), 0.86 (0.850.88) and 0.88 (0.860.91),
respectively. Sensitivities were 0.69 (0.600.75), 0.77
(0.690.84) and 0.88 (0.760.96), and specificities
were 0.82 (0.760.90), 0.81 (0.750.88) and 0.78
(0.720.82), respectively. CAP values were influenced
by several covariates, including NAFLD, diabetes and
BMI. The authors proposed adapting the proposed cutoff
values by adding 10 (95% CI: 4.517) dB/m for
NAFLD/NASH patients, 10 (95% CI: 3.516) dB/m
for diabetic patients and 4.4 (95% CI: 3.85.0) dB/m
per BMI unit.
A study has indicated that histologic steatosis grade
3 and high CAP values independently affect the diagnos-
tic performance of CAP (Jung et al. 2014).
A recent study reported that in patients with
NAFLD, CAP values >300 dB/m may lead to overesti-
mation of liver fibrosis assessed by TE, especially in
patients with lower stages of fibrosis (Petta et al. 2017).
However, the influence of steatosis on LSM in NAFLD
remains debated.
M and XL probes
Two studies compared the performance of CAP
with M and XL probes using liver biopsy as the
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236 Western patients with chronic liver disease (mean
BMI: 24.4 § 6.3), the performances and cutoff values
were similar (de Ledinghen et al. 2017), whereas in
another study conducted in 57 NAFLD Chinese patients
(mean BMI: 30.2 § 5.0), performance was similar, but
cutoff values were higher with the XL probe
(Chan et al. 2017). Thus, further studies are necessary
before any firm conclusions can be drawn.
Comparison with the US signs of liver steatosis
Few studies, all carried out with small samples, are
available. Only two studies have performed a head-to
head comparison with liver biopsy as reference: one in
patients with chronic liver disease (de Ledinghen
et al. 2012a) and the other in patients with chronic hepa-
titis B (Xu et al. 2017a). Both studies indicated that the
performance of CAP for detecting and grading liver stea-
tosis was higher than that of US; however, the rate of
overestimation was significantly higher for CAP than for
US (30.5% vs. 12.4%, p < 0.05) (Xu et al. 2017a).
A study that has assessed the diagnostic accuracy of
CAP in comparison with US for detection and quantifi-
cation of hepatic steatosis in the general population
reported that CAP significantly correlated with steatosis;
the AUROCs were 0.94 (95% CI: 0.910.97) for signifi-
cant steatosis and 0.95 (95% CI: 0.900.99) for severe
steatosis (Carvalhana et al. 2014). It has been reported
that in patients with advanced liver fibrosis, CAP per-
forms better than US in assessing liver steatosis
(Ferraioli et al. 2016b). The US findings of liver fibrosis
and steatosis could be similar, and this may decrease the
diagnostic accuracy of US. No data in NAFLD patients
are available.
By use of the imperfect gold standard methodology
in a series of overweight or obese children, it has been
reported that for the evaluation of liver steatosis in chil-
dren, CAP performs better than US, and a cutoff value
for CAP of 249 dB/m rules in liver steatosis with 0.98
(0.970.98) specificity (Ferraioli et al. 2017).
Comparison with magnetic resonance (proton density fat
fraction)
Studies that have assessed the diagnostic accu-
racy of CAP compared with proton density fat frac-
tion (PDFF) magnetic resonance (MR) spectroscopy,
using liver biopsy as reference, have reported that
CAP is outperformed by MRI-PDFF for steatosis
grading. In a study on 142 patients with NAFLD,
CAP identified hepatic steatosis grade 2 with an
AUROC of 0.73 (95% CI: 0.640.81), whereas
PDFF yielded an AUROC of 0.90 (95% CI:
0.820.97, p < 0.001) (Imajo et al. 2016). In another
study on 55 patients suspected of having NAFLD,both PDFF and CAP detected histologically proven
steatosis (S1), but PDFF had better diagnostic accu-
racy than CAP in terms of AUROCs (0.99 vs. 0.77,
respectively; p = 0.0334) (Runge et al. 2017). Like-
wise, another study in 104 consecutive patients
reported that MRI-PDFF is more accurate than CAP
in detecting all grades of steatosis in patients with
NAFLD (Park et al. 2017). MRI-PDFF identified
steatosis of grade 2 or 3 with AUROC values of 0.90
(95% CI: 0.820.97) and 0.92 (95% CI: 0.840.99);
CAP identified steatosis of grade 2 or 3 with AUROC
values of 0.70 (95% CI: 0.580.82) and 0.73 (95%
CI: 0.580.89).
A study that assessed the accuracy of CAP using
magnetic resonance spectroscopy as the reference stan-
dard in HIV-infected patients found that the results
obtained with the two techniques correlated well; how-
ever, patients with higher body composition parameters
were more likely to be misclassified as having hepatic
steatosis by CAP (Price et al. 2017).
Follow-up
Longitudinal studies are awaited. Recently, a
study that followed up 4282 patients who had both a
reliable LSM and 10 successful CAP measurements
reported that neither the presence nor the severity of
hepatic steatosis predicted liver-related events, cancer
or cardiovascular events in the short term, while
LSM and etiology independently predicted liver-
related events (Liu et al. 2017). Subgroup analyses of
viral hepatitis (hepatitis B: 37.0%, hepatitis C: 2.9%)
and NAFLD patients (40.7% of the entire cohort)
revealed similar results.
Summary
The controlled attenuation parameter is a promising
point-of-care technique for rapid and standardized stea-
tosis quantification, but needs to be better validated in
patients with NAFLD with the XL probe. CAP quality
criteria are not well defined. There are no consensual
cutoff values, and the influence of BMI and diabetes
should be further explored. More data are needed with
the XL probe in NAFLD patients, who are the target
population, and for the comparison with US, taking liver
biopsy as the reference standard. Longitudinal studies
are awaited. CAP is outperformed by MRI-PDFF.
Current technological advances of imaging ultra-
sound systems are directed at grading steatosis. How-
ever, no studies are available yet.
RECOMMENDATION 15: CAP is a point-of-care,
standardized and reproducible technique, promis-
ing for the detection of liver steatosis. However, for
quantifying steatosis there is a large overlap
between adjacent grades, there are no consensual
Fig. 1. Rule of 5. cACLD = compensated advanced chronic liver disease; VNT = varices needing treatment. Reprinted, with permis-
sion, from de Franchis and Baveno (2015).
Table 3. Items to be delineated when performing liver elastog-
raphy studies
2432 Ultrasound in Medicine & Biology Volume 44, Number 12, 2018cutoffs and quality criteria are not well defined.
(LoE 3, GoR C) (10,0,0)Machine(s) utilized, procedure (transient elastography, point shear
wave elastography, 2-D shear wave elastography), probe, quality
criteria
Population (body mass index, alcoholism, comorbidities, transaminase
levels, platelet count)
Context of use (specialty clinic, general practice, academic institution,
etc.)
Confounding factors (fasting, etc.)
Operators (number, degree of training, experience)
Reference standard for validation study and interventional studies
If liver biopsy is used for gold standard; size of specimens, central
reading, interval between liver biopsy and elastographic procedurePractical advice for interpretation of liver stiffness
values
There is significant overlap of stiffness values for
the varying degrees of liver fibrosis. All techniques have
high accuracy for normal patients and most patients with
cirrhosis. However, degrees of liver stiffness between
these two extremes overlap substantially. One approach
is to use a cutoff value system as recommended by the
SRU, with a low cutoff below which there is a high prob-
ability of being normal or having minimal fibrosis and a
high cutoff value where there is a high probability of sig-
nificant fibrosis or cirrhosis (Barr et al. 2016a). Some
patients with biopsy-proven cirrhosis have had relatively
low stiffness values in many studies. Another clinical
approach to interpreting liver stiffness values would be
in keeping with that recommended for TE by the Baveno
VI Conference (de Franchis and Baveno 2015). The so-
called “rule of 5” (Young’s modulus 5, 10, 15 and 20
kPa) could be recommended (Fig. 1): LS <5 kPa has a
high probability of being normal; LS <10 kPa, in the
absence of other known clinical signs, rules out compen-
sated advanced chronic liver disease. Values between 10
and 15 kPa are suggestive of compensated advanced
chronic liver disease, but need further tests for confirma-
tion. Values >15 kPa are highly suggestive of compen-
sated advanced chronic liver disease. Values 2025
kPa can rule in CSPH.
Recommendation 16: Interpretation of liver
stiffness measurements needs to be taken in context
with the other clinical and laboratory data. (LoE 1b,
GoR A) (10,0,0)Minimal requirements for future studies
When studies evaluating liver elastography are per-
formed, it is recommended that the items in Table 3 be
included in the methodology, to allow for better compar-
ison between studies and techniques. The Statement for
Reporting Studies of Diagnostic Accuracy (STARD
checklist) should be used before starting studies of diag-
nostic accuracy.
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